Latest Vascular endothelial growth factor Stories
Research shows that, of 11 popular supplements analyzed, 7 do not adhere to proven formulas; all 11 have misleading claims SAN FRANCISCO, Dec.
Conference Call Scheduled for Wednesday, December 3rd to Provide Investor Update SAN DIEGO, Dec. 2, 2014 /PRNewswire/ -- Lpath, Inc.
Treatment of Visual Impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) and Diabetic Macular Edema (DME) are the Second and Third Indications for Eylea(®) in Canada
TARRYTOWN, N.Y., Dec. 1, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S.
CRESTWOOD, Ky., Nov. 20, 2014 /PRNewswire/ -- Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals.
LONDON and NEW YORK, November 19, 2014 /PRNewswire/ -- [[CENTER] ]http://www.abmrg.com/Global-Oncology-Market---Trends-Forecast-and-Pipeline-Analysis.html
-- Tanibirumab is a novel VEGFR2-neutralizing mAb for treating cancers SHENYANG, China and DAEJEON, Korea, Nov.
TARRYTOWN, N.Y., Nov. 18, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd.
ROCKVILLE, Md., Nov.
CYRAMZA now approved both as a single-agent treatment and in combination with chemotherapy INDIANAPOLIS, Nov.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.